ACRV Acrivon Therapeutics, Inc. Short-Term Debt to Equity
This daily price chart for Acrivon Therapeutics (ACRV) is based on the operations of a precision therapy biopharmaceutical environment, where the AP3T proteomic tool links medical centers with treatment protocols. The current indicator is 0.01. Shareholders trust the ethical standing of Acrivon Therapeutics, which utilizes the APAM system for precise patient selection. The brand's high scientific status is confirmed by its ability to accurately predict therapy outcomes.
%3A%20Short-Term%20Debt%20to%20Capital%20Coefficient&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_ACRV_-_Acrivon-Therapeutics_-_Short-Term-Debt-to-Capital-Coefficient "Acrivon (ACRV) Short-Term Debt to Capital: for the period 04/28/2023 - 10/31/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for acrivon.com (ACRV)
This indicator measures the proportion of short-term liabilities (with maturities exceeding one year) within the equity structure, determining liquidity risk in an environment of high borrowing costs. For Acrivon Therapeutics (ACRV), whose oncology drug development remains independent of economic cycles, analyzing the ratio of short-term loans to equity allows for an assessment of the company's financial stability in the face of key clinical growth triggers.